UA96980C2 - Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки - Google Patents

Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки

Info

Publication number
UA96980C2
UA96980C2 UAA200909229A UAA200909229A UA96980C2 UA 96980 C2 UA96980 C2 UA 96980C2 UA A200909229 A UAA200909229 A UA A200909229A UA A200909229 A UAA200909229 A UA A200909229A UA 96980 C2 UA96980 C2 UA 96980C2
Authority
UA
Ukraine
Prior art keywords
mucosal
injury
deterioration
damage
amount
Prior art date
Application number
UAA200909229A
Other languages
English (en)
Ukrainian (uk)
Inventor
Израэль Риос
Синтия Татхилл
Original Assignee
Сайклон Фармасютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклон Фармасютикалс, Инк. filed Critical Сайклон Фармасютикалс, Инк.
Publication of UA96980C2 publication Critical patent/UA96980C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается способа уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки ротовой полости и/или пищевода, которая является следствием облучения субъекта, который подвергается лучевой терапии рака головы и шеи, который включает введение указанному субъекту эффективного количества иммуномодуляторного соединения формулы А.
UAA200909229A 2007-02-13 2008-02-11 Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки UA96980C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13

Publications (1)

Publication Number Publication Date
UA96980C2 true UA96980C2 (ru) 2011-12-26

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909229A UA96980C2 (ru) 2007-02-13 2008-02-11 Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки

Country Status (14)

Country Link
US (2) US7906486B2 (ru)
EP (1) EP2120986A4 (ru)
JP (1) JP2010518160A (ru)
KR (1) KR20090119897A (ru)
CN (1) CN101657210A (ru)
AR (1) AR065338A1 (ru)
AU (1) AU2008216799A1 (ru)
CA (1) CA2677749A1 (ru)
IL (1) IL200364A0 (ru)
MX (1) MX2009008641A (ru)
NZ (1) NZ579570A (ru)
TW (1) TW200845958A (ru)
UA (1) UA96980C2 (ru)
WO (1) WO2008100458A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96980C2 (ru) * 2007-02-13 2011-12-26 Сайклон Фармасютикалс, Инк. Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
CA2107460A1 (en) 1991-04-01 1992-10-02 Vladimir K. Khavinson Pharmaceutical dipeptide compositions and methods of use thereof
AU2905092A (en) 1991-10-28 1993-06-07 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1994020063A2 (en) 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
US5744452A (en) 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US6060452A (en) 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
US20050256042A1 (en) 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
CN1964731A (zh) 2004-05-14 2007-05-16 希克龙制药公司 用免疫调节剂化合物治疗或预防呼吸道病素性感染
US8193152B2 (en) 2004-10-27 2012-06-05 The Board Of Regents Of The University Of Texas System Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
WO2006116053A1 (en) 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
BRPI0711567A2 (pt) 2006-04-20 2011-11-08 Sciclone Pharmaceuticals Inc uso de um composto imunomodulador para tratamento de melanoma
US20100029652A1 (en) 2006-12-18 2010-02-04 Achillion Pharmaceuticals, Inc. Combination Therapy For Treating Hepatitis C Infections
UA96980C2 (ru) * 2007-02-13 2011-12-26 Сайклон Фармасютикалс, Инк. Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
JP2010536854A (ja) 2007-08-23 2010-12-02 サイクローン・ファーマシューティカルズ・インコーポレイテッド 肺ガンの治療
CN102171186A (zh) 2008-08-06 2011-08-31 赛生制药有限公司 采用免疫调节剂化合物治疗或预防丙型肝炎

Also Published As

Publication number Publication date
MX2009008641A (es) 2009-09-14
AU2008216799A1 (en) 2008-08-21
CA2677749A1 (en) 2008-08-21
EP2120986A2 (en) 2009-11-25
TW200845958A (en) 2008-12-01
KR20090119897A (ko) 2009-11-20
NZ579570A (en) 2012-02-24
IL200364A0 (en) 2010-04-29
WO2008100458A3 (en) 2008-11-27
US7906486B2 (en) 2011-03-15
CN101657210A (zh) 2010-02-24
WO2008100458A2 (en) 2008-08-21
US20110117211A1 (en) 2011-05-19
AR065338A1 (es) 2009-06-03
JP2010518160A (ja) 2010-05-27
US20100086622A1 (en) 2010-04-08
EP2120986A4 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
WO2009067397A3 (en) Treatment for solid tumors
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2009048778A3 (en) Laminins, derivatives, and compositions including same and method for their therapeutic use
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
WO2020033838A3 (en) Treatment of egfr-mutant cancer
ZA201101517B (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases,and uses thereof
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
UA96980C2 (ru) Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
WO2010039920A3 (en) Boldine compounds for promoting bone growth
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
WO2014203074A3 (en) Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
WO2010011599A3 (en) Pimethixene derivatives for promoting bone growth
WO2010141143A3 (en) Engineered avirulent bacteria strains and use in medical treatments
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex